Diabetes Education News

Continuous glucose monitors have the potential to alleviate burdens, improve neonatal outcomes and predict disease progression for pregnant women with type 1, type 2 or gestational diabetes, according to two diabetes experts.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today Co-editor, talks with Camille Powe, MD, about benefits of use of continuous glucose monitoring during and after pregnancy.

ORLANDO — In this video exclusive, James R. Gavin III, MD, PhD, Healio | Endocrine Today Co-editor, talks with Camille Powe, MD, about use of continuous glucose monitoring during pregnancy for women with type 1 diabetes.

A 5:2 intermittent fasting diet combined with meal replacement resulted in greater weight loss and better glycemic control compared with antidiabetic medications in patients with early-stage type 2 diabetes, data from the EARLY study showed.

ORLANDO — Since 2005, an Irish diabetes in pregnancy program has steadily improved pregnancy and neonatal outcomes through extensive research and development of services for care before, during and after pregnancy.

ORLANDO — Adding continuous glucose monitoring to hospital standard of care does not appear to improve glycemic control for adults with type 2 diabetes, according to results of the TIGHT study.

ORLANDO — Semaglutide reduces risk for cardiovascular events among adults with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or change in HbA1c, according to data from the SELECT trial.

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.

ORLANDO — Semaglutide use was associated with significant reductions in worsening of kidney disease, cardiovascular events and all-cause death vs. placebo for adults with type 2 diabetes regardless of concomitant use of SGLT2 inhibitors.

Teva Pharmaceuticals announced it has launched the first generic version of a GLP-1 receptor agonist in the United States, liraglutide 1.8 mg.